AdaptVac

Bavarian Nordic A/S ’s respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV, has missed the mark in the Phase III VANIR trial in older adults, but the firm is confident it can meet its fina

In early 2022, Paul Chaplin, President and CEO of Copenhagen-based Bavarian Nordic A/S , was readying for a “rather heavy loss for the company.” “It was going to be a challenging year, both because i

Pfizer/BioNTech Get Full FDA Approval For Vaccine The US Food and Drug Administration’s full approval of Pfizer Inc. / BioNTech SE ’s COVID-19 vaccine BNT162b2, now Comirnaty, has expanded the compan